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Fatal factitious Cushing syndrome (Münchhausen’s
syndrome) in a patient with macroprolactinoma
and silent corticotrophinoma: case report and
literature review
Carlos André Minanni1, Ana Luiza De Almeida Cardoso1, Edoarda Vasco de Albuquerque Albuquerque1,
Luciana Pinto Brito2, Ludmilla Malveira Lima Lopes1, Andrea Glezer1, Elisa Del Rosario Ugarte Verduguez3,
Berenice Bilharinho De Mendonça2, Marcello Delano Bronstein1, Marcio Carlos Machado1 and
Maria Candida Barisson Villares Fragoso1,4*
Abstract
Münchhausen’s syndrome (MS) is a chronic factitious disorder characterized by the intentional production of clinical
symptoms without external incentive. One type of MS is factitious Cushing syndrome, an extremely rare clinical
situation in which the diagnosis is challenging mainly due to interference of the exogenous medication in cortisol
immunoassays. We described a 26-year-old woman who was originally diagnosed with a macroprolactinoma and
during follow-up developed clinical and laboratorial hypercortisolism. A transsphenoidal surgery was performed and
immunohistochemistry revealed positive and diffuse staining for both hormones. Four years later, her hypercortisolism
recurred and the confirmation of factitious Cushing syndrome was delayed due to conflicting laboratorial results.
There are few cases in the literature of factitious Cushing syndrome, and only one had a fatal outcome. The diagnosis
of this condition is complex and includes cyclic Cushing syndrome in the differential diagnosis. These patients have
high morbidity and increased mortality risk and are likely to have other psychiatric disorders. Prednisone was identified
as the culprit in the majority of the cases.
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Background
Münchhausen’s syndrome (MS) is a chronic factitious
disorder characterized by the intentional production of
clinical symptoms without external incentive [1]. One type
of MS is factitious Cushing syndrome, an extremely rare
clinical situation in which the diagnosis is challenging
mainly due to interference of the exogenous medication in
cortisol immunoassays [2].
Case presentation
A 26-year-old married female former health professional,
who was previously treated for depression, was originally
diagnosed with a macroprolactinoma due to secondary
amenorrhea and galactorrhea. During follow-up she devel-
oped clinical and laboratorial hypercortisolism (Table 1)
and a transsphenoidal surgery was performed despite the
control of serum prolactin (PRL) levels with high doses of
cabergoline (0.5 mg/day). Immunohistochemistry revealed
positive and diffuse staining for PRL and ACTH; the
pattern of ACTH staining was typical of a corticotro-
pinoma (diffuse cytoplasmic staining in corticotroph
cells), whereas the pattern of PRL staining was atypical
(no characteristic Golgi-like pattern of immunoreactiv-
ity seen in lactotroph adenomas). There was also no
evidence of lactotroph differentiation by ultrastructural
analysis. After surgery, PRL levels were controlled without
cabergoline, no glucocorticoid replacement was necessary
and clinical and hormonal control was obtained.
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Four years later, the patient presented with typical, albeit
sporadic, signs and symptoms of Cushing syndrome
(CS) paralleled by intermittent hypercortisolism, indicating
potential cyclic CS. Exogenous intake of glucocorticoids
was strongly denied by the patient. A progressive wors-
ening of the clinical features of CS was evident, with
the onset of diabetes and hypertension (Table 2). At
that time, a chemiluminescence immunoassay (Immulite
2000/Siemens Healthcare Diagnostics) revealed markedly
elevated urinary total cortisol levels (UTC = 12,200 μg/
24 h reference values = 50–310 μg/24 h), although the
morning serum cortisol level was normal (Fs = 12 μg/dL).
The patient’s midnight salivary cortisol level was elevated
(salivary F = 0.2–2.3 μg/dL – RR < 0.12 μg/dL), as mea-
sured using a manual ELISA Millipore kit (Fig. 1), and
plasma ACTH measurements were within the reference
interval at 14 pg/ml (reference values = 10-46 pg/ml) by
chemiluminescence immunoassay (Immulite 2000/Sie-
mens Healthcare Diagnostics). The DHEA-S level was low
(208 ng/ml – RR 988 – 3,400 ng/ml) according to electro-
chemiluminescence immunoassay (Roche Diagnostics,
Sidney, Australia), although the serum PRL levels were
normal. Abdominal CT showed normal adrenal glands
and pituitary MRI exhibited a cystic lesion similar to the
previous tumor tissue, but could also represent an arach-
noid cyst (Fig. 2 A).
To further investigate the discordance between UTC
and morning serum cortisol, urinary free cortisol
(UFC) was measured by high-pressure liquid chroma-
tography tandem mass spectrometry (HPLC/MS).
These results revealed a UTC level of 6 μg /24 h (RV = 3–
43 μg/24 h) and a suppressed morning serum cortisol level
(1.6 μg/dL – normal 7 up to 25 μg/dL), in contrast to the
previous results.
The psychiatric evaluation did not identify any mental
disorder, although the psychological evaluation identified a
complex familial relationship, especially involving her
father, who had a history of alcoholism and had left home
when she was a teenager. The patient presented a fragile
ego, with predominant defense mechanisms of projection,
negation, somatization and reactive reactions. Before the
result of UFC, bilateral adrenalectomy was suggested to the
patient in order to control the hypercortisolism, and the pa-
tient agreed to the treatment despite all the risks, showing a
desire to get healthy and to be pregnant as soon as possible.
Table 1 Hormonal profile during the follow-up
Exam Mar/2006 Jan/2010 Aug/2013 Normal range
Before TS* After TS** Recurrence
ACTH 43 27 24 <46 pg/mL
Salivary cortisol (midnight) 0.13 <0.1 2.49 <0.12 μg/dL
Overnight DST§ 4.1 NA 15.1 <1.8 μg/dL
24-h UTC NA 132 12,200 50 - 310 μg/24 h
Serum cortisol (morning) 19.6 11.4 33 5 - 25 μg/dL
DHEA-S 2,246 NA 208 988 – 3,400 ng/mL
LH 1.1 0.2 0.9 14.0 – 95.6 IU/L
FSH 1.7 <1 2.4 4.7 – 21.5 IU/L
E2 42.6 <13 <15 85.8 – 498.0 pg/mL
Prolactin 57 13.3 27 4.8 – 23.3 ng/mL
TSH <0.03 <0.03 0.58 0.27 – 4.20 μIU/mL
Free T4 1.2 0.97 0.63 0.93 - 1.70 ng/dL
GH 0.6 <0.1 <0.1 <4.4 ng/mL
IGF-I 179 75 26 152.7 – 396.5 ng/mL
*Using bromocriptine 5 mg/day, **Using cabergoline 0.5 mg/day, TS: transsphenoidal surgery, §Dexamethasone suppression test
Table 2 Biochemical findings during hospitalization
Exam Aug/2013 Normal range
Sodium 140 135 - 145 mEq/L
Potassium 4.4 3.5 – 5.0 mEq/L
Calcium 9.1 8.60 – 10.20 mg/dL
PTH 41 15 - 65 pg/mL
25OH vitamin D 18 30 - 100 ng/mL
Urea 25 10 - 50 mg/dL
Creatinine 0.61 0.50 – 0.90 mg/dL
HbA1C 7.2 4.1 – 6 %
Glucose 130 70 - 100 mg/dL
HDL-cholesterol 51 <65 mg/dL
LDL-cholesterol 129 <130 mg/dL
Cholesterol 342 <200 mg/dL
Triglycerides 1,514 <150 mg/dL
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During hospitalization and despite the multidisciplin-
ary treatment approach, the patient showed persistent
hypercortisolism and high levels of triglycerides, amylase
and lipase.
Abdominal CT at this time showed bilateral atrophic ad-
renal glands and severe pancreatitis, and since she had low
cortisol laboratory values, a hydrocortisone stress dose
was administered. The pancreatitis, however, had a fatal
outcome. Additionally, high levels of serum prednisone
and prednisolone (7.4 μg/dL and 97 μg/dL, respectively –
RR < 0.1 μg/dL - HPLC/MS) were demonstrated and, after
her death, her husband found several prednisone tablets at
their home.
Discussion
There are few cases in the literature of factitious CS, and
only one has reported a case with a fatal outcome [3].
The diagnosis of this condition is complex and includes
cyclic CS in the differential diagnosis. The difference be-
tween these possible diagnoses is the periodicity of hor-
mone fluctuation, which can take years in the case of
cyclic CS but can change dramatically over short periods
of time in factitious CS [4–6]. Another clue can be pro-
vided by DHEA-S measurements, as ACTH-dependent
CS is associated with normal/high levels of this hor-
mone. In our case, variations from 100 to 12,000 μg/
24 h in UTC levels could be observed from one day to
the next, and DHEA-S levels were suppressed.
Immunoassays for Fs and UTC demonstrated variable
cross-reactivity with synthetic corticosteroids and their
metabolites; these variations can range from 6 % for
prednisone to 62 % for prednisolone, depending on the
kit, and can lead to a false elevation of Fs [4,7]. A reli-
able ACTH assay is crucial for differentiating ACTH-
dependent from ACTH-independent Cushing syndrome.
However, the performance of ACTH immunoassays has
Fig. 1 Evolution of UTC, salivary F and serum F during follow-up, normalized by the upper limit normal range (ULNR)
Fig. 2 MRI sequences during follow-up. (A) May/2007: coronal view on T 1-weighted MRI of the pituitary gland identified a heterogeneous solid
macroadenoma (1.9x1.8 cm of diameter – arrow). (B) August/2013: MRI after four years of transsphenoidal surgery – questionable remnant tumor
tissue or arachnoid cyst (arrow)
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been questioned recently after several case reports
showed unsuppressed ACTH levels in factitious CS, as
in our patient [2, 7]. In addition, the intermittent intake
of glucocorticoids could lead to fluctuating levels of
ACTH [7]. In the few cases of factitious CS in the litera-
ture, synthetic glucocorticoids detected in blood and
urine by HPLC/MS confirmed the diagnosis since this
method can discriminate similar molecules with a differ-
ent mass to charge ratio [2].
The diagnosis of factitious CS represents a challenge
to the physician. These patients have high morbidity and
increased mortality risk and are likely to have other psy-
chiatric disorders. Among the patients’ profiles described
in the literature (22 cases – Table 3), 80 % were female,
with a median age of 38 years. The medical history of
these cases included drug addiction in 19 % and psychi-
atric disorders in 57 %, mainly depression and anxiety,
and 42 % of patients had personal contact with health
professionals. In regard to laboratory tests, 48 % of
cases showed unsuppressed ACTH levels, and 66 %
also showed elevated UFC at the same time [1–3, 6–11,
13, 14]. In addition, one-third of patients presented a
suspicious pituitary MRI [1,7]. Only three cases in the
literature reported DHEA-S measurements, and all of
them were suppressed [1, 9]. Half of the reported pa-
tients showed normal adrenal glands on abdominal im-
aging [1–3, 6, 9–12]. Prednisone was identified as the
culprit in the majority of the cases [1, 3, 10, 12].
Conclusions
The current case reported a patient with chronic facti-
tious CS with a fatal outcome. Factitious CS is an im-
portant diagnosis to consider in the evaluation of
patients with apparent hypercortisolism; of particular
importance is the recognition of discordant hormonal
data among urinary and serum cortisol levels, ACTH
and DHEA-S associated with atrophic adrenal glands on
CT scan. In addition, HPLC/MS analysis of blood and
urine steroids is the definitive test for the diagnosis of
factitious CS and should be performed when there is a
clinical suspicion of glucocorticoid mishandling.
Table 3 Clinical and laboratorial data from 22 patients with factitious Cushing’s syndrome from review of literature
Authors Age
(year)
Gender 24 h
UC
DST Serum
cortisol
Plasma
ACTH
Pituitary MRI Adrenal CT Medication
Witt, 1981 [10] 15 F Up Suppression Up N Normal Normal Prednisone
Cook, 1985 [14] 33 F Lo Absent Up N Normal NA NA
O’Hare, 1986 [11] 22 M Up Suppression V N Normal Normal Hydrocortisone
Anderson, 1993 [12] 46 F N NA Lo NA Normal Normal Prednisolone
Anderson, 1993 [12] 23 F Lo NA N NA NA Normal Prednisone
O’Shaughnessy, 1995 [7] 37 F Up Suppression Up N Questionable Normal Prednisolone
Workman, 1995 [13] 33 F Up Suppression N N NA NA Hydrocortisone
Cizza, 1996 [1] 37 F V Paradoxical Up Up Microadenoma Normal Prednisolone/
Dexamethasone
Cizza, 1996 [1] 31 M Up Absent Up Lo Microadenoma Atrophy Cortisone
Cizza, 1996 [1] 44 F Up NA N N Questionable Normal Unknown
Cizza, 1996 [1] 32 F V Suppression Lo NA Questionable Atrophy Unknown
Cizza, 1996 [1] 36 F NA NA Lo Lo Normal Left-sided
mass
Prednisolone
Cizza, 1996 [1] 31 F Lo NA Lo Lo Normal Atrophy Prednisone
Villanueva, 2000 [9] 37 F Lo NA Lo NA NA NA Dexamethasone
Villanueva, 2000 [9] 57 F V NA V Lo Normal Normal Dexamethasone
Villanueva, 2000 [9] 47 F NA NA V Lo Normal Right-sided
mass
Unknown
Villanueva, 2000 [9] 54 F Lo NA Lo Lo Normal NA Dexamethasone
Ach, 2005 [6] 29 M N NA N N NA Normal Dexamethasone/
Hydrocortisone
Ach, 2005 [6] 60 M N NA N NA NA NA Betamethasone
Kansagara, 2006* [3] 33 F Lo NA Lo N Normal Normal Prednisone
Thynne, 2013 [2] 54 F Up NA V V Normal Normal Prednisolone
NA: not available; Up: upper; Lo: lower; N: normal; V: variable F (female), M(male), DST (dexamethasone suppression test), UC urinary cortisol *Fatal case
Minanni et al. Clinical Diabetes and Endocrinology  (2015) 1:3 Page 4 of 5
Consent
Written informed consent was obtained from the patient’s
husband for publication of this case report and any
accompanying images. A copy of the written consent is
available for review by the Editor-in-Chief of this journal.
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